Christian Pilarsky vividly remembers the moment, in 2022, when he realized that his technique for modelling pancreatic cancer had finally worked. A molecular biologist at the University Hospital ...

ATCC and the Broad Institute report the development of engineered isogenic cancer models designed to replicate resistance to targeted therapies, beginning with osimertinib, the latest-generation ...